Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

NCT01063283 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Bevacizumab 7.5 mg/kg
DRUG: Bevacizumab 15 mg/kg

Sponsor

University of Chicago

Collaborators

[object Object]